A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Clinical trial NCT05581004 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05581004
Sponsor: Genentech, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Solid Tumors NSCLC HNSCC Melanoma TNBC Esophageal Cancer Gastric Cancer Cervical Cancer Colorectal Cancer Urothelial Carcinoma Clear Cell RCC HCC

Start date: 2022-10-20
Primary completion: 2028-07-31
Enrollment: 165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.